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In the U.S., an estimated 40 million noninvasive cardiac
tests are performed annually, and this rate has been increas-
ing by as much as 20% per year (1). This growth is part of
a larger trend of progressive annual increases in total U.S.
spending on medical care, which has accelerated over the
past four years. Rising costs of care reflect both an increase
in the prevalence of disease due to aging of the population
and the development of expensive new diagnostic and
therapeutic technologies for cardiovascular disease. For
cardiologists, cardiac imaging encompasses approximately
30% of all Medicare reimbursement, totaling over $1 billion
in 2000 (2). In the area of atherosclerosis imaging, proce-
dural volume for computed tomography (CT) and mag-
netic resonance imaging (MRI) was 555,652 and 719,329
scans, respectively, in the year 2000 (Siemens Medical
Engineering Group, Magnetic Resonance Division, Ise-
lin, New Jersey), whereas 1999 Medicare utilization of
carotid or peripheral extremity studies was 424,978 (2).
Although no reliable statistics exist on the use of diagnostic
tests to detect asymptomatic atherosclerosis, estimates on the
use of electron beam tomography (EBT) suggest that approx-
imately 300,000 scans are performed annually in 79 centers in
the U.S. (personal communication, Leslee J. Shaw, 2002).
Thus, diagnostic cardiovascular tests are not only a significant
part of modern cardiovascular care; they are also a “big
business.” The economics of this testing, therefore, is of
importance for both clinicians and policymakers.
Economic evaluations, particularly cost-effectiveness analy-
ses, are not simply concerned with costs. Instead, these analyses
combine cost information with relevant clinical outcome data
to provide a measure of the value of a new technology in
relation to relevant alternatives. Unfortunately, very few pub-
lished economic evaluations of atherosclerosis imaging tech-
niques exist (3–9). Two major reasons for this deficiency
can be postulated. First, many of the technological
advances in cardiac imaging were introduced without
undergoing rigorous scientific testing on effectiveness.
Without adequate effectiveness data, economic evalua-
tion is extremely limited. Second, economic analyses are
most straightforward when evaluating therapies that save
lives or improve quality of life. Assessing the value of
tests that incrementally improve a diagnosis or an assess-
ment of prognosis, which may or may not alter outcome,
is more difficult and often yields less persuasive results.
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DEFINING THE EFFECTIVENESS OF
DIAGNOSTIC TESTS FOR ECONOMIC ANALYSIS
General considerations. Any assessment of value for
money begins with the effectiveness side of the equation.
What is the money purchasing? In the case of a new
therapy, money is spent to improve survival or quality of life.
A new diagnostic test is used with the same basic goals. To
improve outcome, however, several intermediate steps must
take place after the test is performed. First, the test results
must be summarized in some clinically meaningful fash-
ion—“positive,” “strongly positive,” “high risk,” and so
forth. Second, the responsible clinician must link the test
results with a subsequent management decision: for exam-
ple, “high risk” equals need for coronary angiography and
revascularization. Third, the therapies associated in this
fashion with the test results must be capable of changing
patient outcomes.
The ultimate value question for a diagnostic test is: “Does
its use improve longevity or quality of life?” A test may fail
to achieve this objective for several reasons. First, a test may
not provide enough useful incremental information to alter
management, because clinicians use the test results incon-
sistently in decision making, because the effectiveness of the
therapy used is inadequate, or because the therapy is of poor
quality. For example, a new test may provide information
regarding diagnosis or risk level that is already available to
the clinician from previously collected data. A 65-year-old
male with typical exertional angina has a high pretest
probability of significant coronary artery disease (CAD).
The addition of a noninvasive stress test to his work-up
would be unlikely to alter management in any important
way, much less alter outcome. Research on diagnostic tests
typically uses an underlying conceptual model that looks at
the total available information content of the test across the
entire spectrum of patient pretest risk level. However,
clinicians make management decisions using a much differ-
ent conceptual model, one that frequently employs heuris-
tics and informal decision thresholds (10). If a test provides
measurably more information about a patient’s risk level but
that information does not move that patient across a
decision threshold, the added information may be invisible
to the clinician and have no effect on management or
outcome. For this reason, multivariable models that show a
new test is significantly better at stratifying risk than an
older test are not, in themselves, sufficient to demonstrate
incremental effectiveness, as we have defined it above.
Another way that test information becomes uncoupled
from patient outcome is when clinicians use the test results
inconsistently. For the test to alter outcome, clinicians as a
group must have a consensus about the management impli-
cation of test results. Several studies have shown that a
significant proportion of symptomatic patients with high-
risk stress nuclear perfusion scan results do not undergo
coronary angiography (11). For such patients, management
does not appear to be significantly altered because of the test
result. The reasons why physicians do not act in the
anticipated manner upon receiving test data are complex
and outside the scope of this report. However, it is impor-
tant to note that the idealized world often reflected in
models of test use, where each test result is closely linked
with a management decision, often does not match the real
world of test use. New tests often become widely dissemi-
nated before there is general evidence-based agreement on
what the results mean. The effect of the test on management
will therefore be inconsistent, thereby reducing any possible
impact on outcomes. The ongoing debate on the meaning
of coronary calcium evident on the EBT test illustrates this
problem well.
A third reason that testing may fail to yield changes in
patient outcome is inadequate effectiveness of the therapies
that are linked to the test results. A strongly positive
atherosclerosis imaging test may lead to a diagnostic cardiac
catheterization, which itself cannot improve outcome and
carries a small procedural risk. Results of the catheterization
in turn may lead to coronary revascularization. The ability of
this therapy to improve prognosis is linked to the severity of
underlying CAD (12). If the imaging test applied to a
cohort of asymptomatic subjects identifies a subset that has
significant CAD, but these patients have predominantly
one-vessel disease, subsequent use of revascularization will
have minimal impact on survival. Because the screened
population is, by definition, asymptomatic, improvement in
quality of life with revascularization is unlikely. Thus,
screening in this example alters management, but a positive
impact on clinical outcomes might be undetectable.
Finally, a test may fail to improve outcome if the quality
of the resulting therapy is poor. Models of test use often
assume that therapies applied in the real world will be of
equivalent quality to the best results available in the pub-
lished data. However, if the “high-risk” test result leads to a
revascularization procedure in a low-volume community
hospital that has a procedural morbidity and mortality rate
several times higher than the expert high-volume centers,
the ability of the test to improve outcomes may be signifi-
cantly reduced. Similarly, if the “high-risk” test result leads
to intensive risk-factor management, but this management
does poorly in achieving target cholesterol levels, blood
pressure control, and smoking cessation, the value of the test
will be proportionately reduced.
For an atherosclerosis imaging test to be clinically effec-
tive in the assessment of asymptomatic individuals, it would
have to provide new information above and beyond that
from the clinical examination (history, physical examina-
tion) and initial laboratory data (e.g., cholesterol level,
glucose, electrocardiogram). One complexity that is not well
appreciated is that the added value of a test in a given cohort
may vary with the baseline characteristics of the subjects
being tested (13). In addition, a test result is most likely to
alter clinical management when used in intermediate-risk
subjects. As reflected in Bayes’ rule, a “negative” noninvasive
test in a high-risk cohort will not be sufficient to make the
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cohort low risk, whereas a “positive” test in a low-risk cohort
will not yield post-test probabilities that are in the high-risk
range. When we require a diagnostic test to change man-
agement and thereby improve outcomes so as to demon-
strate value for money, it might seem as if we are discount-
ing the common practice of using tests, particularly
screening tests, to provide reassurance to the patient. From
an economic analysis perspective, reassurance is a “therapy”
that has the goal of improving the patient’s quality of life.
Use of testing to reassure a patient that he or she is disease
free, for example, can be analyzed using cost-utility analysis
methods (see Cost Utility Analysis section). The challenge
in such an analysis is defining how much and for how long
the quality of life is improved by “good news.”
Problems with determining the effectiveness of screening.
Because screening studies typically involve low-risk popula-
tions, large sample sizes with prolonged follow-up are
required to assess the impact of screening on disease-related
events. Large, randomized trials are the most rigorous
means of determining whether an intervention improves
outcome, but these trials for screening strategies are difficult
to perform and expensive. Large-scale randomized trials
have been performed for screening of some prevalent dis-
eases, such as breast cancer, but not for cardiovascular
disease. Even with such large randomized trials, interpreta-
tion of the results has often been controversial (14–17).
Because of the difficulty in performing randomized trials
of screening for cardiovascular disease, some researchers
have attempted to simulate such a trial using two observa-
tional cohorts, subjects who did and who did not have
screening. Such an approach is subject to several important
biases that may not be correctable analytically. The cohort
that has the screening test has its disease detected at an
earlier stage, introducing “lead-time” bias. Because of the
earlier diagnosis, there is an appearance of improved survival
(longer interval from “diagnosis” to death) in the screened
cohort when in fact this is not the case (18). “Length-time”
bias is another more subtle, yet particularly important
problem in which patients with more aggressive disease are
less likely to undergo screening merely because their disease
becomes clinically manifest before they have an opportunity
to show up for a screening examination (18). “Overdiagno-
sis” bias occurs when screening detects indolent disease that
is highly unlikely to ever be clinically problematic, but leads
to the impression that screening decreases the adverse
impact of the disease (18). An example of this is a
population screening program for neuroblastoma in children
that not only yielded no benefit but also led to the discovery
and treatment of clinically unimportant tumors (19,20).
Traditional survival analyses, including Kaplan-Meier
product limit calculations (21), Cox proportional hazards
regression (22), and parametric modeling (23), are often
used to analyze observational studies of screening programs.
However, these methods are all based on the assumption
that time zero, which is the time that follow-up begins, is
clearly defined, has some kind of clinically or biologically
meaningful substrate, and is not systematically different
between different groups of patients. Assessment of screen-
ing and survival outside of randomized trials is inherently
problematic because time zero is not known for patients not
undergoing screening. This failure to determine time zero
accurately leads to length-time and lead-time biases, which
cannot be rectified by survival models.
Use of decision models to evaluate screening programs.
Because large, randomized trials of atherosclerosis imaging
have not been performed, researchers have often employed
decision-analytic methods to examine alternative screening
strategies. These methods use structured mathematical simu-
lation models to estimate the cost for some benefit achieved.
One major advantage of a modeling approach is the ability to
consider all available evidence rather than to be restricted to the
data from one trial involving a specific limited cohort.
One drawback to the use of a decision model is that
comprehensive data needed to address the questions of
interest are rarely available. Few empirical studies, for
example, have directly compared the accuracy of several
candidate screening strategies, and none have compared all
in a single cohort (24,25). To compensate for a deficiency of
data, decision models use numerous assumptions based on
diverse types of evidence, including expert opinion. The
cobbling together of unrelated fragments of “evidence”
solves the problem of populating the model with the needed
parameters, but it can create the impression in unwary
consumers of greater certainty than is warranted. The
impact of uncertainty on model results can be formally
tested using a sensitivity analysis, which involves varying
each uncertain model parameter over a range of plausible
values and observing the result. Multi-way sensitivity anal-
ysis involves varying more than one uncertain parameter at
a time. Considerable analytical judgment is required, how-
ever, in deciding what to vary and how much variation is
required. Extrapolation of model results from the published
“evidence” to the general population of interest requires the
use of additional assumptions about treatment and target
population characteristics that might not be available or
might be biased (26,27).
A second problem with the use of decision models to
evaluate screening for asymptomatic atherosclerosis is that,
currently, the optimal sequence of testing and screening
intervals is not known. Modeling the possible permutations
in a decision model can become quite complex. Thus, the
analyst is required to make some simplifying assumptions
about the choices the clinician and patient will make.
PRINCIPLES OF ECONOMIC
ANALYSIS RELEVANT TO CARDIAC IMAGING
Medical economics and accounting provide tools to answer
two important questions relevant to any new test or therapy.
First, what does it cost? Second, does it provide reasonable
value for money? To assess the cost question, it is necessary
to estimate not only the cost of the test itself but also the
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stream of costs that occur because the test was used and
would not have otherwise occurred (induced costs). For
example, the hospital or clinic cost to perform an EBT test
may be $100. If the patient receiving that test subsequently
has gated single-photon emission computed tomography
(SPECT) and coronary angiogram, then these later proce-
dures should be counted as part of the total cost of the
strategy of using EBT. Thus, the cost of “screening with
EBT” strategy may be significantly greater than $100 per
patient.
To examine the value question, economic efficiency anal-
ysis is used to compare the incremental costs of the test
strategy with its incremental benefits in a structured format.
Three forms of economic efficiency analysis can be em-
ployed: cost-effectiveness, cost-utility, and cost-benefit. All
three estimate the cost of producing one extra unit of benefit
with the new test strategy relative to the comparison strategy
(i.e., the efficiency with which benefit is generated for
money spent). The most common metric used in cost-
effectiveness analysis is dollars per life-year added. Similarly,
dollars per additional correct diagnosis, per high-risk patient
identified, per cardiac event prevented, or per gram of
myocardium salvaged are also all legitimate measures for a
cost-effectiveness analysis. The major difficulty in using
something other than life-years (or quality-adjusted life-
years in cost-utility analysis, as described later in this
document) is the lack of benchmarks with which to inter-
pret them.
Cost-utility analysis, a modification of cost-effectiveness
analysis, takes account of both the quality and quantity of
life added by the new strategy. Utility is a technical term
that refers to the relative value or preference of the decision
maker for a given health state. Although utility is related to
the concept of quality of life, the techniques to measure it
are different. Quality of life is typically measured with
instruments that assess either functioning or well-being in a
set of domains relevant to health and health care. For
example, the New York Heart Association functional class
measures physical functioning (crudely), whereas the Short
Form-36 (SF-36) assesses both functioning (e.g., physical,
role) and well-being (e.g., emotional) in nine domains.
In contrast, utility measurement evaluates how the asses-
sor (typically a patient with the condition of interest) values
a specific health state relative to defined benchmarks, such
as excellent health (valued at 1.0) and death (valued at 0).
The main utility measurement techniques are the standard
gamble and the time trade-off. Because these are complex to
use, especially in large-scale studies, recent work has favored
the use of health utility indices, such as the EuroQoL.
These indices are health status measures, similar to the
SF-36, that have a finite number of possible health states
reflecting the unique permutations of the component scales.
Each unique health state has an associated population
preference or utility weight, previously measured on a
relevant cohort of patients or future patients (i.e., the
general public). In a cost-utility analysis, length of survival
in a particular health state is combined with the utility
weight for that state. For example, a year of survival with
mild angina that has been given a utility weight of 0.93
would equal 0.93 (1 year  0.93 utility) quality-adjusted
life-years (QALYs).
Cost-benefit analysis is a form of economic efficiency
analysis in which the incremental health benefits created by
the new strategy are converted to their monetary equivalent.
Because of the controversies associated with valuing health
and survival in terms of money, this form of economic
analysis is infrequently used in medicine.
Economic efficiency analysis is always performed incre-
mentally, in relation to an explicitly defined alternative. In
the case of screening programs, the alternative is often “no
screening,” but in some situations, the relevant comparison
may be with an alternative screening test or strategy. The
benefits and costs of the new strategy, then, are those that
occur only in the presence of the new strategy but not with
the comparison strategy.
Cost analysis. The cost of an imaging test can be subdi-
vided into fixed and variable components. Fixed costs do not
change with procedural volume over the short-term. Exam-
ples include rent on testing laboratory space, leasing costs
for test equipment, and salaried employees. These costs will
be the same whether the laboratory is operating at capacity
or sits completely idle. Variable costs change with unit
changes in procedure volume. Examples include disposable
supplies (including contrast agents) and personnel who are
paid only for hours worked. The total cost of a given test is
the variable cost plus a share of the fixed cost. Current
estimated costs of cardiac imaging modalities are reported in
Table 1.
For diagnostic cardiovascular imaging tests, equipment is
a major component of fixed cost. Equipment acquisition
costs vary widely, but may be as much as $1 million to $4
million for MR, positron emission tomography, and multi-
slice CT scanners. In general, equipment for low technology
tests (e.g., treadmill exercise or ankle brachial index) is
much less expensive. Recent innovations for atherosclerosis
imaging include the use of multi-slice (e.g., 16 slice) CT,
higher strength (e.g., 3 tesla [T]) magnets, and MRI
spectroscopic methods. In some cases, existing equipment
can be upgraded at minimal to no cost. For example, most
CT scanners can perform coronary calcium scoring by the
addition of often low-cost software upgrades.
Several accounting methods can be used to allocate fixed
costs. For example, the annual fixed cost may be distributed
equally over the annual volume of cases performed. If a
laboratory is expected to do 1,000 cases, each case would be
allocated 1/1,000 of the annual fixed costs. Thus, higher
volumes tend to lower the fixed component of test cost, at
least until the volume increase necessitates leasing more
space or equipment and hiring more personnel. For new
technologies, many unresolved issues remain that may add
costs, including laboratory standards or certification, imag-
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ing protocols, and evolving equipment (e.g., 4 vs. 16
multi-slice CT or 1.5 T to 3.0 T MR) (28,29).
Induced test costs (savings). Total costs of a testing
strategy include induced downstream costs and savings. The
results of a diagnostic test may lead to one or more
additional tests and therapies (9). If these would not have
been used in the absence of the test, then they constitute
part of the induced cost of the test. Similarly, if the test in
question demonstrates that other tests and therapies, which
would have been done, are not required, these constitute an
induced saving of the test. If the test leads to a therapy that
prevents a future myocardial infarction (MI) or revascular-
ization procedure, these savings should similarly be counted
in the test’s balance sheet. Incidental test findings also drive
downstream costs of care. In a recent report by Hunold et al.
(30) using EBT, noncoronary abnormal findings were noted
in 53% of patients, whereas specific incidental findings (e.g.,
lung disease) were noted in 20% of patients. In a younger
cohort, the prevalence of incidental findings was 9%; one-
third of which were major findings, often requiring invasive
testing (31).
Other cost components. One issue that is rarely consid-
ered in most cost analyses is that the value of screening is
sensitive to patient preferences (32). This is exemplified by
self-referral patterns to EBT where patients’ willingness to
know and pay drive its use as a screening tool. Previous
reports have noted that patients with evidence of coronary
calcium are more likely to consult with their physician,
engage in weight loss, decrease dietary fat intake, and
initiate new aspirin and cholesterol lowering medications
(33). However, this increase in care-seeking behavior may
also lead to an increase in worry and lower thresholds for
coronary revascularization. The net result may be an in-
crease in overall costs of care for this population. Travel
costs, relevant family labor expenses, out-of-pocket costs for
home monitoring and over-the-counter health care prod-
ucts, and insurance deductibles are all indirect costs that
should be considered in an economic evaluation.
Defining cost-effectiveness of a diagnostic test. Cost-
effectiveness analysis explicitly relates incremental costs to
incremental health benefits. The cost-effectiveness ratio
summarizes this relationship in terms of the cost required to
produce one extra unit of benefit with the new testing
strategy relative to the comparison strategy. The cost-
effectiveness ratio takes the general form:
Incremental CE 
CNew  CStandard
HBNew  HBStandard
where CE  cost-effectiveness; C  costs; HB  health
benefits; New  new testing strategy; and Standard 
comparison testing strategy.
The principal benchmarks for the cost-effectiveness ratio
have developed through an informal consensus in the field
and should not be regarded as absolute. In general, a
cost-effectiveness ratio of less than $50,000 per life-year
added is considered “economically attractive” (34–41),
Table 1. Estimated Costs of Common Cardiac Imaging Procedures and Other Laboratory and
Office Visit Costs Using Published and Available Data Sources
Average Cost
(in U.S. $)
Cost Range  Add-ons*
(in U.S. $)
Imaging modalities
Ankle brachial index 61 (40–64)
Carotid ultrasound 71 (62–77)
EBT/CT coronary calcium† 87 (62–90)
Treadmill exercise stress 67 (35–114)
Rest echocardiography 91 (64–342)
Other computed tomography 283 (90–475)
Magnetic resonance imaging 873 (525–1,220)
Positron emission tomography 1,272 (960–1,470)
Single-photon emission tomography 296 (262–574)
Right/left heart catheterization 1,810 (851–4,741)
Intravascular ultrasound‡ 712 (NA)
Comparative costs
Outpatient office visit§ 39 (14–77)
Cholesterol panel 13 (10–22)
High sensitivity C-reactive protein 13 (8–20)
Advanced lipid analysis 247 (170–299)
EBT/CT  electron beam tomography/computed tomography.
*Including contrast or radiopharmaceutical use and technique add-ons (e.g., wall motion). Cost data derived from Refs. 8, 9,
75–79.
†Costs based on a brief report by Hernigou et al. (62) and from direct cost estimates by Shaw et al. (9).
‡Added cost of IVUS was based upon the U.K. National Health Service health technology assessment by Berry et al. (5). Cost
includes equipment and added labor for the United Kingdom and would be expected to vary in other health care systems. Costs
have been inflated to year 2002 and converted to U.S. dollars.
§Cost range is for a new patient seen in an outpatient setting.
Costs were estimated by charges adjusted by national average cost-charge ratio.
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whereas a ratio greater than $100,000 per life-year added is
considered “economically unattractive.” The intermediate
range is an economic gray zone, and many well-accepted
medical-care programs fall into this area.
These cost-effectiveness benchmarks represent a state-
ment of societal willingness to pay for incremental health
benefits. Thus, it follows that countries that spend more on
health care (such as the U.S.) would be willing to accept a
higher threshold for defining the zone of economic attrac-
tiveness than would countries that spend less.
Use of intermediate-outcome measures. As discussed ear-
lier, much of the existing cardiac imaging outcomes data do
not effectively link test results with post-test decision
making in terms of the initiation of therapies that alter the
outcome of a patient. Cost-effectiveness analysis has tre-
mendous limitations when applied to noninvasive testing
because the link between diagnosis and end results is often
unknown and must be simulated in a model (42).
Given the difficulty of linking testing strategies with
changes in patient outcome, some have recommended the
use of intermediate-outcome measures, such as the cost to
identify coronary disease or a cardiac event (6). An
intermediate-outcome model would require fewer assump-
tions and extrapolations of long-term prognosis and would
rely more upon actual observational data. The major diffi-
culty with this type of model is that it generates a cost-
effectiveness ratio for which no benchmarks have been
established. Furthermore, use of an intermediate-outcome
measure in a cost-effectiveness ratio does not allow for
comparison across an array of medical therapeutic regimens
and programs, which can be useful in using economic
analysis to inform policy decision making.
The available evidence is mixed as to whether atheroscle-
rotic imaging techniques in asymptomatic individuals add
important management information over and above that
contained in the Framingham risk index (43,44). For
example, in the Rotterdam Study, carotid intima-media
thickness measured in the common carotid artery did not
improve the estimation of stroke or MI over and above a
standard risk factor assessment (receiver operator character-
istics [ROC curve index 0.75 vs. 0.72]; although both risk
factors and ultrasound measures were equally predictive
(ROC curve index  0.72 vs. 0.71).
Subgroup effects in cost-effectiveness analysis. A cost-
effectiveness ratio is not a precise point estimate, although it
is often presented that way, and it is sensitive to multiple
demographic variables such as age, gender, the risk of the
disease, and the analysis perspective (e.g., society, patient,
payer) (42,45). For screening, cost-effectiveness ratios often
become more favorable beyond a given age or risk level
(where disease is more prevalent) (46,47). Further, the
proportional benefit of drug treatment is highly related to
the underlying risk in the patient population (48 –50).
For both these reasons, imaging screening tests are
generally more cost-effective in higher-risk population
subsets in which the test is diagnostically and prognos-
tically more accurate. For example, using a decision
model to simulate the cost-effectiveness of screening
1,000 men undergoing Doppler ultrasound for the detec-
tion of carotid artery disease during a 20-year time
period, a one-time screening program in a high risk
subset of the population had a cost-effectiveness ratio of
$35,130 as compared to $52,588 per QALYs gained for
lower risk individuals (51).
LESSONS FROM
SCREENING FOR PRECLINICAL CANCER
Given the limited data currently available on screening for
atherosclerosis, it is instructive to examine lessons learned
and challenges encountered in using diagnostic tests to
screen for non-CAD preclinical disorders. Much work has
been performed in developing screening for preclinical
cancer. Like atherosclerosis, cancer is a major cause of adult
morbidity and mortality, and it accounts for a substantial
portion of clinical health care spending. Our review of this
area is intended to be illustrative rather than comprehensive
or authoritative.
Lung cancer. Lung cancer is responsible each year for the
greatest number of cancer deaths among adults in the U.S.
By the time the disease becomes clinically evident, it is
usually at an advanced stage. Five-year survival rates average
about 15% (52). Thus, the disorder seems an ideal one to
screen for preclinical early-stage resectable tumors. Initial
randomized trials employed chest radiographs and sputum
cytology (18). In about 37,000 male smokers over age 45,
screening detected more early stage resectable tumors, and
initial results suggested improved survival. However, no
reduction in lung cancer mortality was ultimately demon-
strated with the screening intervention. Screening appeared
to achieve its objective (increased detection of early-stage
preclinical disease), but ultimate outcome was unaffected.
Some of the uncoupling between diagnosis and outcome has
been attributed to the biology of the disease. Even small
tumors, at the threshold of radiographic detectability, may
have metastasized. Thus, by the time these tumors were
detected by radiographic screening, they were beyond the
point of surgical curability. In addition, it appears that
another subgroup of tumors detected by preclinical screen-
ing was prognostically insignificant, and their early detec-
tion led to extra procedures without improving survival. In
short, lung cancer screening appeared to fail because a
significant proportion of tumors detected were either too
advanced to cure or were clinically unimportant. A new
generation of studies is examining the utility of a more
sensitive screening test for lung cancer, low-dose helical CT
scans, but it is unclear that this test will be able to rectify the
limitations of earlier screening technologies.
Colorectal cancer. Colorectal cancer is the third most
common cause of cancer deaths in U.S. adults. Most of
these cancers arise from adenomatous polyps, although less
than 1% of such polyps give rise to cancer. As with lung
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cancer, the rationale for screening is that early detection and
removal of preclinical cancers or precancerous polyps will
increase survival. Most studies of screening for colorectal
cancer have examined the utility of fecal occult blood
testing, while a few have evaluated direct imaging studies
such as sigmoidoscopy or colonoscopy (53). A recent sys-
tematic review of cost-effectiveness analyses of colorectal
cancer screening found six relevant studies (53). Each used
a simulation model to combine published outcome data
with cost data from Medicare and prior published reports
(53). In these models, screening with any of the major tests
currently employed was economically attractive (cost-
effectiveness ratios ranging from $6,000 to $40,000 per
life-year saved). However, these results are dependent on
the reasonableness of the starting assumptions and, for most
of the screening tests examined, there is little empirical
randomized trial evidence to validate the survival benefits
projected by these models. The uncertainty in these models
also makes it impossible to confidently identify the most
economically attractive testing strategy from among the
possible candidates (53).
Summary. Thus, although some favorable trial data sup-
port the use of occult blood testing to reduce colon cancer
mortality, similar data is lacking for use of widely advocated
imaging techniques, such as colonoscopy. Further, empirical
trial support for screening for lung cancer is quite limited, as
are data for screening for preclinical atherosclerosis. Screen-
ing does identify more early stage cases (i.e., it does risk
stratify the population) and does lead to more invasive
therapy, but the assumption—without empirical valida-
tion—that meeting these two criteria will lead to the desired
result, improved patient outcomes, is clearly not warranted.
Unfortunately, screening for preclinical disease seems so
“reasonable,” so much in concordance with “common
sense,” that the absence of adequate proof of desired
effectiveness is often overlooked. In fact, screening may
become so accepted that it is considered unethical to subject
the screening strategy to a randomized test (54). Economic
analyses performed in this environment are often built on
weak evidence and may extrapolate even beyond this base to
“discover” attractive screening strategies that have never
been empirically tested.
COST EFFECTIVENESS OF PRECLINICAL
ATHEROSCLEROSIS IMAGING: CURRENT EVIDENCE
Initial cost estimates for screening asymptomatic popu-
lations. In the U.S., there are approximately 30 million
Americans age 50 or older may be eligible for asymptomatic
atherosclerosis screening, depending on how the target
population is defined (55–59). The cost of screening alone
could add $3 billion to our global health care costs.
Detection of high-risk abnormalities ranges from 5% to
46%, depending on the age and degree of comorbidity in the
population (60,61). Therefore, additional diagnostic tests
following the initial screen could substantially increase the
total costs, as discussed earlier (9,30,31).
Cost-effectiveness studies. There are no large prospective
studies or published models describing the costs of screen-
ing intermediate-risk asymptomatic individuals for evidence
of atherosclerosis are lacking. The deficiency of high-quality
data comparing the costs and outcomes of different screen-
ing strategies poses a severe limitation for economic analysts
wishing to examine the cost-effectiveness of alternative
strategies. Consequently, we review the few studies that
present cost analyses of the use of EBT, carotid duplex
scans, and ankle brachial index measurement in lower-risk
symptomatic populations. Although these often are not
directly relevant, they do serve to illustrate some of the
issues germane to screening in asymptomatic subjects. In
addition, we present some data from a model that has not
yet been published to illustrate some of the potential
pressure points in using these tests in asymptomatic sub-
jects.
Four studies have examined the use of EBT. The first
adapted a published decision model of diagnostic testing to
compare five different testing strategies in symptomatic,
ambulatory patients being evaluated for obstructive CAD (6).
The five testing strategies were angiography alone, or
exercise treadmill, stress echocardiography, stress myocar-
dial perfusion imaging, or EBT, followed by angiography as
indicated. Four different cut points for EBT calcium scores
were considered. The major data used to drive the model
results were taken from published diagnostic sensitivities
and specificities. The “cost” of each testing strategy in this
analysis was the cost of the initial screening test performed
plus the cost of angiography for that proportion of the
population presumed to be referred following an abnormal
initial screening examination. “Cost effectiveness” was cal-
culated as the average cost of testing per correct diagnosis of
CAD. In a low prevalence cohort, this analysis found the
EBT strategies to have the lowest cost per CAD patient
correctly identified. However, this result was simply a
consequence of three key assumptions: 1) in the absence of
testing, no correct diagnoses would be made and no patients
would be referred for angiography; 2) the cost of EBT was
about one-third of stress echocardiography or stress myo-
cardial perfusion imaging; and 3) the accuracy of EBT was
equivalent to both of these tests.
The second EBT analysis used a similar model to
compare the cost of identifying significant CAD with
exercise treadmill, myocardial perfusion imaging, or EBT in
symptomatic patients with a low to intermediate pretest prob-
ability (7). This model predicted a significant cost savings
per correct diagnosis with EBT. These results were similar
to what the investigators observed in an empirical cohort of
207 patients with a low to intermediate probability of CAD.
The results of the model were driven by assumptions of cost
for EBT that were only slightly higher than for exercise
testing plus an improved diagnostic accuracy.
Both of these reports present simplified models of diag-
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nostic evaluation and contain no outcome data. A third
study reported on the costs to identify coronary disease
events (death or MI) in a cohort of 676 asymptomatic
subjects with one or more cardiac risk factors who were
referred for EBT (9). Patients were followed for an average of
3.5 years after testing. Cost estimates were based upon
direct health care costs within the Hospital Corporation of
America hospital system; costs were also varied in a sensi-
tivity analysis based on prior studies. The screening EBT
cost per patient was $90 (62). Total screening and treatment
costs were $1,923 per patient for low-risk subjects and
$4,621 per patient for intermediate-risk subjects. Screening
identified 2.6 per 100 low-risk subjects who had a subse-
quent cardiac event and 8.9 per 100 intermediate-risk
subjects with a subsequent event. The cost per event
identified was $73,000 in low-risk subjects and $37,260 in
intermediate-risk subjects. Considering only death events,
screening identified 5 per 1,000 deaths in low-risk subjects
at a cost of $402,000 per death identified. In the
intermediate-risk patients, screening identified 4.3 deaths
per 1,000 at a cost of $108,400 per death identified. As
noted earlier, there are no benchmarks available to interpret
a cost-effectiveness ratio expressed as dollars per death
identified. If each one of those “deaths identified” could be
converted to “lives saved” with appropriate therapy and
these saved patients lived an additional 15 or 20 years (mean
age of screened cohort was 51), then it is possible that this
screening could be economically attractive when valued in
terms of dollars per life year saved. However, the pivotal
point in this entire sequence is the assumption that EBT
screening identifies patients who will die and allows their
deaths to be prevented. As noted in the Section on Lessons
from Screening for Preclinical Cancer, stratifying the risk of
future clinical disease development and death with a test is
not equivalent to showing that screening with that test will
save lives.
The fourth study reviewed was a detailed decision analysis
of the cost-effectiveness of EBT screening and follow-up
testing in a cohort of 1,000 asymptomatic 40-year olds was
examined (8). This analysis modeled the cost-effectiveness
of screening EBT using decision analysis (Fig. 1) methods
to determine: 1) the marginal cost per detection of “at-risk”
patient, and 2) the projected marginal cost per QALYs,
using favorable assumptions about the efficacy of primary
prevention and the independent prognostic value of EBT.
“At-risk” was defined as having a probability of a coronary
event greater than or equal to 1% per year. This cutoff was
chosen because primary prevention has been proven to be
cost-effective only when risk exceeds this threshold, there-
fore identifying a population in whom intervention can
make a difference—the goal of any screening program (63).
As such, the prevalence of “at-risk” participants in this
cohort was 7.2% using the Framingham risk model, rising to
22.4% when incorporating the results of EBT.
The costs for all variables were as follows: further cardio-
vascular testing was estimated at $400 if the initial
follow-up test (e.g., exercise stress test) was normal, and
$1,400 if abnormal (to include a cardiac catheterization).
The annual cost of medications (such as statins, beta-
blockers, aspirin, and perhaps angiotensin-converting en-
zyme inhibitors) was assumed to be $300. The cost of
incidental abnormalities ranged from $50 for a minor
finding requiring only a visit or phone call to reassure the
patient, to $1,200 for a major finding (often requiring
invasive procedures, such as a liver biopsy for a hepatic
lesion, or bronchoscopy for perihilar lymphadenopathy).
The baseline cost for EBT was $400, assuming there was no
repeat scanning for progression.
Figure 1. Decision model for the evaluation of an asymptomatic 40-year-old man. This is an example of a decision analytic model showing the basic
decision and subsequent chance nodes of the typical path a person undergoing screening for cardiovascular risk. Abn  abnormal; Nl  normal.
1913JACC Vol. 41, No. 11, 2003 Mark and Shaw et al.
June 4, 2003:1855–917 Task Force #5—Is Atherosclerosis Imaging Cost Effective?
The marginal cost of identifying each additional patient
“at risk” missed with the Framingham risk model was
$9,789 in the base case. This cost per diagnosis was most
sensitive to the cost of EBT itself and the cost of medica-
tions. Changing the cost of the test to $800 increased the
marginal cost per diagnosis to $12,421; halving the test cost
to $200 resulted in a cost per diagnosis of $8,474. Varying
the annual cost of medications from $100 to $600 changed
the marginal cost from $5,276 to $16,565. The cost per
diagnosis was not sensitive to other variables, or to the cost
or frequency of incidental findings. Simultaneously varying
the cost and frequency of incidental scan findings over a
wide range changed the cost per diagnosis by less than or
equal to $1,500.
The marginal cost per QALY saved for the base case was
$86,752. This marginal cost was most sensitive to the
efficacy of primary prevention, the utility placed on a year of
life on medications, and the independent prognostic value of
EBT. Because the purpose of any screening program is to
intervene early and thereby improve outcomes, this analysis
assumed a five-year decrement in survival, and a large
relative risk reduction of 30%, which yields an 18-month
increase in survival in those patients “at-risk.” The marginal
cost-effectiveness of screening EBT is very sensitive to the
relative reductions in mortality. As the efficacy of primary
prevention decreases, so does the life expectancy of those at
risk, and as the relative risk decreases to 25%, EBT becomes
dominated by the Framingham Risk Model alone. If an
intervention existed that would decrease mortality by 35%,
the cost per QALY would fall to $36,076. This indicates
that unless early intervention can reduce mortality by at least
25%, screening EBT would not provide any added value in
this analysis. Thus, in this model, screening EBT costs at
least $86,700 per QALY saved, despite liberal assumptions
about the efficacy of primary prevention and the added
prognostic value of EBT. However, this analysis was based
on the value of screening a relatively young, low-risk
population. These results would not be generalizable to
older populations with a greater prevalence of intermediate
risk individuals.
The adverse impact of screening tests is something that
often goes unappreciated. In this model, although the
impact of incidental findings was only marginal, the impact
of even small but sustained decrements in health status (as
reflected by utilities) had a powerful negative effect on the
cost-effectiveness of the test. There are no data that directly
assess the utility of being “at-risk” owing to coronary artery
calcium on EBT, or any atherosclerosis imaging test. One
study has shown that having calcification was associated
with increased worry and hospitalization (33). In the Beaver
Dam Health Outcomes Study, Fryback et al. (64) found
that patients with hypertension valued a year of life at 94.4%
relative to patients without hypertension. Hypertension is a
reasonable surrogate for being diagnosed as “at-risk” because
in both conditions the patient is asymptomatic but requires
serial follow-up and interventions, including medications.
Further research is needed to better understand the impact
of screening imaging on quality of life in order to incorpo-
rate the patient’s perspective into any screening imaging
efficacy.
One study has examined the cost of routine screening for
carotid and lower extremity arterial disease in 206 patients
referred for abdominal aortic aneurysm repair (65). This, of
course, represents a cohort with known advanced athero-
sclerosis in at least one portion of the arterial tree. Cost of
testing was assigned using Medicare reimbursements. Ca-
rotid duplex scans revealed significant carotid stenosis
(greater than or equal to 60%) in 18% of patients. Lower-
extremity Doppler studies with ankle brachial index
determinations revealed significant peripheral vascular
disease in 12% of patients. Seventy-one percent of
patients with advanced carotid disease and 83% with
advanced peripheral arterial disease had overt clinical
evidence of their disease. The cost of screening was
$5,445 per advanced carotid stenosis identified and
$3,732 per advanced peripheral vascular disease identi-
fied. Selective screening restricted to symptomatic pa-
tients was substantially less expensive.
Serial testing or monitoring for changes in risk: use of
imaging as a surrogate outcome. The analyses described
so far consider simple testing strategies where a positive
screening test leads to the definitive diagnostic test and
therapy. However, a “real world” alternative for manage-
ment of asymptomatic individuals with lesser abnormalities
or with intermediate-risk imaging results is the use of serial
tests. In this setting, serial testing is defined as a repeat use
of the initial screening examination to identify progressive
changes or improvements as a result of risk-factor reduction
or other therapeutic interventions. For example, a baseline
carotid MRI scan could be followed at one to two years with
an additional MRI scan after intensive statin therapy. In this
manner, changes from baseline to one-year on the imaging
test serve as surrogate outcomes. Serial testing requires
defining significant thresholds of change. The aim of serial
testing is to identify patients who have progressive disease in
the setting of ongoing risk-factor management and who
require more aggressive management. It appears from EBT
that calcium score changes of approximately 25% over one
to two years are more often associated with an increased risk
of nonfatal MI (66). Greater thresholds of change would be
required for patients with smaller abnormalities or for
modalities that are less reproducible, especially in nonexpert
hands (67). Imprecision and lower reproducibility will drive
unnecessary testing and costs. Serial testing at one-year
intervals using Doppler ultrasound for screening of asymp-
tomatic carotid atherosclerotic disease was found to be
cost-ineffective in one study (51).
In the use of any imaging modality for serial monitoring,
subsequent medical management or risk-reducing strategies
should be clearly identified. To date, medical management
following asymptomatic screening and based upon evidence
of subclinical disease or other risk markers has not been
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adequately evaluated. However, statin treatment has been
reported to halt progression of atherosclerotic disease, as
determined by a number of cardiac imaging modalities
(68–72). In a recent crossover design clinical trial in 66
patients with coronary calcium (low-density lipoprotein
[LDL] greater than 130 mg/dl) receiving cerivastatin (0.3
mg/day), the median annual relative increase at 14 months
in coronary calcium was 25% during the untreated versus 9%
during the treatment period (p is less than 0.0001) (70).
None of these prior reports, however, have considered the
specifics of medical management nor examined marginal
differences between 1) one or more atherosclerosis imaging
techniques (e.g., CT vs. MRI) as compared with 2) the
Framingham risk equation and, possibly, emerging low-cost
laboratory parameters (e.g., high sensitivity C-reactive pro-
tein).
Establishing clinical pathways for testing and down-
stream procedure use. One additional strategy is to exam-
ine a clinical pathway of care that includes the initial clinical
risk assessment, screening test, and follow-up diagnostic
procedure. Fayad et al. (73) have proposed one such
approach where low cost treadmill exercise electrocardio-
graphic testing is recommended for those patients with an
intermediate CT calcium score. Additionally, for patients
who have a high-risk CT calcium score, CT angiography
and MR plaque characterization are recommended. This
strategy attempts to allocate more expensive resources to
those higher-risk individuals. As with many of the other
strategies discussed above, no data on the economics of this
management strategy have yet been presented, and large-
scale outcome studies remain to be done.
HEALTH POLICY IMPLICATIONS AND CONCLUSIONS
Traditionally, medical decisions are made at the patient-
physician level and focus on risks and benefits for the
individual patient. Doctors are often poorly informed about
the costs of tests and therapies they use, and patients are
often insulated from these costs by insurance. Advances in
medical diagnosis and therapy tend to progressively increase
medical costs. However, payers are increasingly unwilling to
spend more resources on health care. Theoretically, at least,
these conflicts are resolved at the policy level. Policymakers
are supposed to translate societal desires for health care and
societal willingness to pay into a coherent program.
Finally, economic analysis is primarily a tool to inform
the health policy debate. High-quality economic analysis, in
turn, is heavily dependent on high-quality clinical outcome
data. Currently, screening is an accepted strategy for reduc-
ing the morbidity and mortality of certain serious diseases
through early detection and intervention (74). In the arena
of screening for preclinical atherosclerosis, however, neither
the clinical database nor the economic data have reached a
satisfactory level of maturity. Thus, whether atherosclerosis
imaging techniques could further reduce coronary heart
disease mortality at an economically attractive price remains
to be established.
FUTURE DIRECTIONS
1. Cost-effectiveness data are increasingly being applied to
the evaluation of imaging technology. A requisite
amount of high-quality clinical effectiveness data is
necessary for the determination of an added economic
benefit. To date, for atherosclerosis imaging, there is a
paucity of high-quality clinical outcomes and economic
data for review. Thus, an important need exists for
long-term outcomes data to be developed for all of the
newer imaging modalities in order to inform potential
models of cost-effectiveness.
2. Standards for defining cost-effectiveness include the
amount of resources or costs required so as to achieve a
given clinical benefit. Such standards have been devel-
oped from therapeutic intervention data and models.
Benchmarks and thresholds for defining cost-effective
care defined by those standards may not be directly
applicable to the use and application of imaging modal-
ities to detect subclinical atherosclerosis and define risk
of future events. As such, professional societies and
stakeholder government agencies as well as senior leaders
in health care economic analysis should convene to create
and define standards for evaluating imaging procedures
with regard to costs and outcomes.
3. Current clinical and economic effectiveness analyses are
hampered by a lack of clinical algorithms with noted
inputs for serial testing, post-test treatment strategies,
resultant proportional risk reduction, as well as induced
resource consumption levels with a variety of atheroscle-
rosis imaging modalities. Future research in the area of
atherosclerosis imaging must provide more definitive
data regarding to the links between the initial imaging
procedure and results and subsequent downstream test-
ing and treatment effectiveness.
4. The aim of a cost-effectiveness analysis is to guide health
care payers and regulators in the evaluation of new
therapies and technologies in the setting of standards for
use, reimbursement, and for approving use. Substantial
additional data are needed for virtually all currently
available and developing modalities of atherosclerosis
imaging prior to the support of any techniques being
considered as cost-effective.
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